NeuBase疗法

NBSE NASDAQ
4.670
-0.130
-2.71%
已收盘, 16:00 08/21 EDT
开盘
4.940
昨收
4.800
最高
4.940
最低
4.600
成交量
4.25万
成交均量(3M)
16.06万
52周最高
6.28
52周最低
1.582
换手率
0.25%
市值
7,971.86万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供NeuBase疗法 NBSE股票价格,NeuBase疗法股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

NeuBase Therapeutics, Inc., formerly Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin.
展开 >

最近浏览

名称
价格
涨跌幅